Patient P-01543
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
75%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 58 GI-04 recommended — GI Support Protocol GI-04
- Day 59 Patient accepted — Started GI-04 in the companion
- Day 67 GI symptom burden −32% vs expected — GI Support Protocol GI-04
- Day 70 ME-01 recommended — Monitoring Escalation ME-01
- Day 71 Patient accepted — Started ME-01 in the companion
- Day 73 Tolerance state changed — Unstable → Improving
- Day 74 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 49.
Primary contributors, last 14 days
- GI instability+11
- Toxicity-6
- Inflammatory activity+4
- Treatment adherence-4
- Nutritional resilience-2
What helped?
- GI Support Protocol GI-04Day 58Result: symptom burden −32%
- Monitoring Escalation ME-01Day 70Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
63%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑75
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 47
- WearableHRV 36 ms, trending down
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 47 and rising
- Autonomic recovery ↑45
- WearableResting HR 79 bpm
- Wearable2,037 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 44/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 37 ms
- Sleep
- 7.4 h
- Steps
- 3,138
- Resting HR
- 81 bpm
Daily log: GI score 47, nutritional resilience 49, adherence 43.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01365 | 53% | S14 | SC-12 | improved | 49 |
| P-01706 | 53% | S14 | GI-04 | improved | 55 |
| P-01473 | 52% | S14 | GI-04 | improved | 51 |
| P-01556 | 52% | S14 | GI-04 | improved | 44 |
| P-01400 | 51% | S17 | GI-04 | improved | 51 |
| P-01438 | 51% | S14 | GI-04 | improved | 56 |
| P-01611 | 50% | S14 | GI-04 | improved | 44 |
| P-01627 | 50% | S14 | GI-04 | improved | 54 |
| P-01649 | 50% | S14 | GI-04 | improved | 46 |
| P-01570 | 49% | S14 | SC-12 | improved | 46 |
| P-01458 | 48% | S14 | GI-04 | improved | 44 |
| P-01614 | 48% | S14 | GI-04 | improved | 53 |